J. Goldman & CO LP Iveric Bio, Inc. Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $4.34 Million - $6.56 Million	-165,407 Reduced 93.69%	11,136 $438,000
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $2.41 Million - $3.16 Million	-128,835 Reduced 42.19%	176,543 $4.3 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $4.67 Million - $6.49 Million	270,971 Added 787.55%	305,378 $6.54 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $1.7 Million - $3.36 Million	-180,808 Reduced 84.01%	34,407 $617,000
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $1.19 Million - $2.47 Million	-130,492 Reduced 37.75%	215,215 $2.07 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $2.15 Million - $2.98 Million	176,794 Added 104.67%	345,707 $5.82 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $1.85 Million - $2.51 Million	133,650 Added 379.01%	168,913 $2.82 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $249,309 - $617,102	35,263 New	35,263 $573,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.